Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies-Reference-Cited by-同舟云学术

Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies

Published:2017-08-25 Issue:24 Volume:123 Page:4851-4859
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Abaza Yasmin M.¹^ORCID,Kadia Tapan M.¹^ORCID,Jabbour Elias J.¹,Konopleva Marina Y.¹,Borthakur Gautam¹,Ferrajoli Alessandra¹,Estrov Zeev¹,Wierda William G.¹,Alfonso Ana¹,Chong Toh Han²,Chuah Charles³,Koh Liang‐Piu⁴,Goh Boon‐Cher⁴,Chang Julie E.⁵,Durkes Daniel E.⁶,Foudray Maria Cielo¹,Kantarjian Hagop M.¹,Dong Xiao Qin¹,Garcia‐Manero Guillermo¹

Affiliation:

1. Department of LeukemiaThe University of Texas MD Anderson Cancer CenterHouston Texas

2. Division of Medical OncologyNational Cancer Centre Singapore Singapore

3. Cancer and Stem Cell Biology Program, Duke‐National University of Singapore Graduate Medical School Singapore, Singapore General Hospital Singapore

4. Department of Hematology and OncologyNational University Cancer Institute, National University Hospital Singapore

5. Division of Hematology and OncologyUniversity of Wisconsin Paul B. Carbone Comprehensive Cancer CenterMadison Wisconsin

6. MEI Pharma IncSan Diego California

Funder

S*Bio

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.30949

Reference34 articles.